Compare HITI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | NERV |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.8M | 210.1M |
| IPO Year | 2021 | 2014 |
| Metric | HITI | NERV |
|---|---|---|
| Price | $2.31 | $4.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.13 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 315.1K | 151.9K |
| Earning Date | 06-15-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $23.73 | N/A |
| Revenue Next Year | $12.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $1.76 |
| 52 Week High | $4.06 | $12.46 |
| Indicator | HITI | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 51.96 |
| Support Level | $2.20 | $3.80 |
| Resistance Level | $2.60 | $4.70 |
| Average True Range (ATR) | 0.08 | 0.34 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 68.35 | 71.08 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.